Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Clinical trial NCT06282874 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06282874
Sponsor: Guangdong Association of Clinical Trials
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Brain Metastases Leptomeningeal Metastasis

Start date: 2024-08-01
Primary completion: 2026-04-30
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.